GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT01290549
- Locations
- 🇺🇸
M.D Anderson Cancer Center; Oncology, Houston, Texas, United States
🇺🇸Florida Cancer Specialists; Sarasota, Sarasota, Florida, United States
🇫🇷Centre Hospitalier Regional Universitaire de Lille, Lille, France
A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2013-11-27
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 319
- Registration Number
- NCT01287117
A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT01287091
- Locations
- 🇺🇸
Investigational Site, Austin, Texas, United States
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2016-10-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT01283373
A Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of Cobimetinib in Healthy Participants
- First Posted Date
- 2011-01-17
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01277718
A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion
- First Posted Date
- 2011-01-14
- Last Posted Date
- 2014-04-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 202
- Registration Number
- NCT01277302
A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-12-22
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 336
- Registration Number
- NCT01264939
A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 147
- Registration Number
- NCT01258907
Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer
- First Posted Date
- 2010-12-06
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01254526
An Absolute Bioavailability Study in Healthy Participants Comparing Oral to Intravenous Administration of GDC-0973 (Cobimetinib)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-11-29
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT01249118
© Copyright 2024. All Rights Reserved by MedPath